N-Propyltryptamine
Pharmaceutical compound
From Wikipedia, the free encyclopedia
N-Propyltryptamine (NPT) is a serotonin receptor modulator of the tryptamine family related to N-methyltryptamine (NMT).[1][2][3] According to Alexander Shulgin in his book TiHKAL (Tryptamines I Have Known and Loved), NPT is not known to have been tested in humans.[1] It acts as a serotonin receptor agonist in the rat uterus and stomach strip, with slightly lower potency than dimethyltryptamine (DMT).[4][3] However, in contrast to DMT and NMT, NPT did not cause central effects in dogs.[2][5] It is said to be less toxic than dipropyltryptamine (DPT) in rodents.[1] The chemical synthesis of NPT has been described.[1][6] NPT was first described in the scientific literature by Speeter and Anthony by 1954.[2][4][3][5] Subsequently, the drug was described by Shulgin in TiHKAL in 1997.[1]
- None
| Clinical data | |
|---|---|
| Other names | NPT; N-n-Propyltryptamine |
| Drug class | Serotonin receptor modulator |
| ATC code |
|
| Identifiers | |
| |
| PubChem CID | |
| ChemSpider | |
| Chemical and physical data | |
| Formula | C13H18N2 |
| Molar mass | 202.301 g·mol−1 |
| 3D model (JSmol) | |
| |
| |